Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
Go back to Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases| Celgene Corp. (NASDAQ: CELG) | Delayed: 108.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.24 | 52 Week High | $127.00 | |||
| Open | $7.85 | 52 Week Low | $93.05 | |||
| Day High | $108.24 | P/E | 32.12 | |||
| Day Low | $108.24 | EPS | $3.37 | |||
| Volume | 0 | |||||
| (NASDAQ: EDIT) | Delayed: 2.80 +0.11 (4.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.69 | 52 Week High | $43.99 | |||
| Open | $2.70 | 52 Week Low | $12.43 | |||
| Day High | $2.88 | P/E | N/A | |||
| Day Low | $2.69 | EPS | $0.00 | |||
| Volume | 2,919,003 | |||||
